Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Holding BPMC?
Track your performance easily
BPMC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$43.89 - $121.90
Previous Close$86.43
Volume1.54M
Average Volume (3M)677.50K
Market Cap
$5.79B
Enterprise Value$5.77B
Total Cash (Recent Filing)$763.60M
Total Debt (Recent Filing)$740.35M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Oct 24, 2024EPS Estimate
-$0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.42
Shares Outstanding63,345,465
10 Day Avg. Volume486,482
30 Day Avg. Volume677,497
Standard Deviation0.14
R-Squared0.05
Alpha0.00537
Financial Highlights & Ratios
Price to Book (P/B)18.08
Price to Sales (P/S)15.96
Price to Cash Flow (P/CF)-30.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.90
Enterprise Value/Gross Profit23.95
Enterprise Value/Ebitda-31.85
Forecast
1Y Price Target
$125.82Price Target Upside45.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Blueprint Medicines News
PremiumPre-Earnings
Is BPMC a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnother beat-and-raise quarter based on a strong launch of Ayvakit in ISM.
Market ExpansionThe launch of Ayvakit in Germany and strong international performance can offset any seasonality.
Revenue GrowthAyvakit sales were $114.1M, well above consensus estimates and representing significant quarter-over-quarter and year-over-year growth.
Bears Say
Guidance MessagingThere is some confusion around the messaging of the guidance, which management has 'more confidence' in but that only requires an anemic 2.5% q/q growth in the next two quarters to reach the midpoint.
Investor SentimentInvestor sentiment suggested buyside expectations into the Q were higher than our street-high estimates, with significant investor skepticism about the sincerity of the initial guidance, as well as the revised guidance.
Shares PressureShares are under pressure on a view that the upwardly revised guidance reflects seasonal headwinds and limited demand.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $43.89 and its highest was $121.90 in the past 12 months.
What is Blueprint Medicines’s market cap?
Currently, no data Available
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is Oct 24, 2024 which is in 46 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on Aug 01, 2024. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.286 by $0.486.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -$0.98.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 63,345,467 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.286. Following the earnings report the stock price went down -7.396%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Among the largest hedge funds holding Blueprint Medicines’s share is Woodline Partners LP. It holds Blueprint Medicines’s shares valued at 95M.
---
Blueprint Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$125.82 (45.57% Upside)
$125.82 (45.57% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 230.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.8%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
72.68%
12-Months-Change
Fundamentals
Return on Equity
-65.09%
Trailing 12-Months
Asset Growth
8.78%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
BPMC Company Deck
---
BPMC Earnings Call
Q2 2024
0:00 / 0:00
---
BPMC Stock 12 Month Forecast
Average Price Target
$125.82
▲(45.57% Upside)
Technical Analysis
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+15.50%
reiterated a buy rating 8 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +15.50% per trade.
---